# Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

> **NCT05588453** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kari Kendra** · enrollment: 30 (estimated)

## Conditions studied

- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8

## Interventions

- **BIOLOGICAL:** Natural Killer Cell Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05588453
- **Lead sponsor:** Kari Kendra
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-04-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05588453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05588453, "Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05588453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*